One of the lowest globally, India?s Case Fatality Rate 1.76% and sliding, Health Ministry issues FAQs

 

 

 

India continues to report one of the lowest COVID Case Fatality Rates when compared to several other countries. While the global CFR stands at 3.3% as on date, the comparative figure for India is 1.76%.

 

The deaths per million population in India is one of the lowest in the world. While the global average is 110 deaths /million population, India is reporting 48 deaths /million population. The comparative figure for Brazil and the UK is 12 and 13 times higher, respectively.

 

As part of the COVID management and response policy, there has been a sharp focus of the Central Government on not only containing the COVID related fatality, but to reduce deaths and to save lives by providing quality clinical care to the critical and severe patients of COVID. Collaborative efforts of the Union and State/UT governments have resulted in strengthening of the health facilities across the country. 1578 Dedicated COVID Hospitals are providing quality medical care. The Central Government has also issued the Standard of Care guidelines incorporated in the Clinical Treatment Protocol.

 

A unique initiative to build the capacities of the ICU doctors in clinical management of critical patients towards reducing the fatality, e-ICU has been started by AIIMS, New Delhi. Twice a week, on Tuesdays and Fridays, tele/video -consultation sessions are held by knowledge and domain experts for the doctors manning ICUs in the State hospitals. These sessions started from 8th July 2020.

 

 

 

Till date, 17 tele-sessions have been held, and 204 institutions have participated in them.

 

The FAQs are dynamic in nature, drawing from the experience and knowledge collected during clinical management of the COVID critical care patients in the ICUs. As new challenges are posed by the treating doctors, and new concerns raised and addressed by them, the document shall be accordingly updated incorporating the evolving knowledge.

 

 

Hydroxychloroquine (HCQ) has been advised as prophylaxis in HCW and high-risk contacts without contraindications. It can be used along with proper use of PPE and other infection control practices to protect from COVID 19.

 

Ivermectin has been found to be a potent inhibitor of SARS CoV2 replication in vitro, but the doses required to achieve this effect in vivo far exceeds the usual dose. It is currently not recommended in the national guidelines but can be used in patients in whom HCQ is contraindicated.

In our experience, there have been no delayed post-COVID thrombotic complications. Since the prothrombotic state parallels the viremic and inflammatory phase, once the patient has been discharged, the thrombotic risk also decreases. So, we don’t recommend anti-coagulation at discharge in routine COVID patients unless indicated for other reasons like DVT, prosthetic valve etc.

 

Sudden deaths have been reported both at presentation to emergency department (ED) as well as in hospital. Reasons that have been proposed include a sudden cardiac event/ ACS, preceding silent hypoxia that went unnoticed or due to a thrombotic complication such as pulmonary thromboembolism. Patients with risk factors to develop severe COVID or with prior comorbid conditions such as CAD or chronic lung disease should be strictly monitored for their saturation. They should not be allowed to move unattended. Anticoagulant should be used in all at-risk patients who do not have any risk factors of bleeding.

 

 

Corticosteroids are currently indicated in moderate to severe COVID-19 patients. Recovery trial has used dexamethasone. However, both IV dexamethasone or methyl prednisolone may be used based on the availability.

 

 

Tocilizumab has been approved by DCGI on compassionate ground in view of ongoing pandemic. However, it is an experimental therapy, has a limited role, and should be used only in patients with cytokine syndrome after ruling out active infections.

 

 

Convalescent plasma collected from ABO matched donors with high neutralizing titers can be given to patients at risk of developing severe COVID in early stages of the disease. However, it should also be considered an experimental therapy and should be used with caution.

 

 

Studies have used Favipiravir mainly in mild or asymptomatic COVID, claiming to prevent progression, whereas majority of this cohort recover with just supportive care and monitoring and usually require no specific therapy. Evidence is weak for the use of Favipiravir and is currently not recommended in national guidelines.

 

 

There is no evidence to support the use of antifibrotic agents like pirfenidone in preventing COVID related fibrosis and hence should not be used. 

 

Depression is a common finding in patients with COVID which may be because of number of reasons including staying in isolation, anxiety related to disease, social stigma, among others. Such patients need empathy and psychological counselling preferably by a trained HCW like a psychologist / psychiatrist.

 

 

Remdesivir/TCZ are experimental therapies, approved by DCGI in view of the ongoing pandemic. Therefore, they should not be used as empirical therapy for suspected cases. You should use these agents only in proven COVID patients, where clinically indicated.

 

 

No, there is no role of methylene blue in the management of COVID.

 

 

Remdesivir is currently recommended for 5 days in once daily dosing.

 

 

There is no evidence to support the use of Remdesivir/TCZ in asymptomatic patients with comorbidities.

 

 

No, relatives are not allowed to visit COVID-19 patients as they have chances to get infected and transfer it to the community.

 

Parents can stay with the children after explaining the risk and taking consent for the same.

 

No, there is no role of steroids at the time of discharge unless indicated for any other concomitant disease.

 

 

Patients on ventilator may require TPN or Ryle’s tube feeding depending on their underlying condition.

 

 

If the patient is not able to maintain saturation, going into respiratory fatigue, or the GCS is poor to tolerate NIV, they should be considered for invasive ventilation.

 

 

Patients in whom prolonged ventilation is anticipated should be considered for tracheostomy.